Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcholinesterase inhibitor therapy in dementia: pharmacogenetic associations with plasma concentrations, interactions, and treatment response
2008-005472-27Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Nov 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of donepezil, galantamine and rivastigmine in Alzheimer's disease (AD) and mixed dementia (3 arms), sponsored by Medical University of Innsbruck. Primary endpoints: CYP2D6 and plasma concentration endpoint, Genotype-phenotype correlation endpoint and 1 more. Started Nov 2008; status: completed.
02
Drugs
donepezilgalantaminerivastigmine
03
Conditions
Alzheimer's disease (AD)mixed dementia
Beyond the preview
Go deeper on 2008-005472-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005472-27.